Company / Accounts Receivable
PUMA BIOTECHNOLOGY, INC. Accounts Receivable History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$53.7M
FY2025
5-year range
$32.0M / $53.7M
FY2021-FY2025
Trend
+67.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 9 years, ranging from $10M in FY2017 to $54M in FY2025.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of +16.0%.
Improved from $48M to $54M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +10.0%
- 5-Year CAGR
- +16.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +16.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 67.6% year-over-year.
- Lowest accounts receivable in the period was in FY2017.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.7M | +67.6% |
| FY2024 | $32.0M | -33.1% |
| FY2023 | $47.8M | +18.6% |
| FY2022 | $40.4M | +24.1% |
| FY2021 | $32.5M | +27.3% |
| FY2020 | $25.5M | -11.6% |
| FY2019 | $28.9M | +39.1% |
| FY2018 | $20.8M | +114.8% |
| FY2017 | $9.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026